At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Apremilastdrug
Likely dose
Apremilast 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Apremilast 30 mg BID Combined With Dupilumab for the Treatment of Recalcitrant Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating Apremilast for Atopic Dermatitis. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Open label phase 2 investigational study of efficacy and safety of apremilast 30 mg twice a day (BID) in chronic atopic dermatitis when added to the FDA approved treatment dupilumab for atopic dermatitis that is not providing adequate clinical responses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
CollaboratorsAmgen
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartAug 2020
Primary CompletionJun 2022
Study CompletionAug 2022
TodayJul 2026
First PostedMar 13, 2020
Enrollment StartAug 1, 2020
Primary CompletionJun 23, 2022
Study CompletionAug 18, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.3 years ago
Interventions
Apremilastdrug
30 mg twice daily (BID)